Poster

May 20, 2021 Poster

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

AUTHORS Gordon, et al
Programs OPN-2853

November 5, 2020 Poster

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

AUTHORS Mims, et al
Programs OPN-2853

November 13, 2019 Poster

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

AUTHORS Pemmaraju, et al
Programs OPN-2853

May 20, 2018 Poster

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

AUTHORS Patnaik, et al
Programs OPN-2853

July 1, 2017 Poster

Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma

AUTHORS Ambrosini, et al
Programs OPN-51107

December 2, 2016 Poster

Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia

AUTHORS Huang, et al
Programs OPN-51107

July 15, 2016 Poster

Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor

AUTHORS Ma, et al
Programs OPN-51107

December 3, 2015 Poster

Efficacy and Mechanismof Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies

AUTHORS Mead, et al
Programs OPN-51107